|
|
|
Volumn 24, Issue 157, 2015, Pages 33-35
|
|
Canagliflozin (INVOKANA°): A "me-too" of the dangerous dapagliflozin
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANAGLIFLOZIN;
DAPAGLIFLOZIN;
HEMOGLOBIN A1C;
METFORMIN;
PLACEBO;
2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL;
ANTIDIABETIC AGENT;
BENZHYDRYL DERIVATIVE;
BIOLOGICAL MARKER;
GLUCOSIDE;
GLYCOSYLATED HEMOGLOBIN;
HEMOGLOBIN A1C PROTEIN, HUMAN;
SLC5A2 PROTEIN, HUMAN;
SODIUM GLUCOSE COTRANSPORTER 2;
THIOPHENE DERIVATIVE;
ANTIDIABETIC ACTIVITY;
ARTICLE;
BLADDER CANCER;
CARDIOTOXICITY;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR EFFECT;
DEHYDRATION;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SAFETY;
FRACTURE;
HUMAN;
HYPOGLYCEMIA;
HYPOTENSION;
KIDNEY FAILURE;
KIDNEY FUNCTION;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
PHOTOTOXICITY;
PREGNANCY;
RISK ASSESSMENT;
UROGENITAL TRACT INFECTION;
ANTAGONISTS AND INHIBITORS;
BLOOD;
DIABETES COMPLICATIONS;
DIABETES MELLITUS, TYPE 2;
METABOLISM;
RISK FACTOR;
TREATMENT OUTCOME;
BENZHYDRYL COMPOUNDS;
BIOLOGICAL MARKERS;
DIABETES COMPLICATIONS;
DIABETES MELLITUS, TYPE 2;
GLUCOSIDES;
HEMOGLOBIN A, GLYCOSYLATED;
HUMANS;
HYPOGLYCEMIC AGENTS;
RISK ASSESSMENT;
RISK FACTORS;
SODIUM-GLUCOSE TRANSPORTER 2;
THIOPHENES;
TREATMENT OUTCOME;
|
|
EID: 84922311040
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (4)
|
|
References (9)
|
